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Contrary to bacterial replicating kinetics, where the doubling time 1.3 days, the proportion of patient with a high viral load would have
varies considerably but often ismeasured inminutes or hours, viral rep-
lication kinetics is calculated in days. A new study by Isabelle Lodding
and colleagues in E-Biomedicine attempts to calculate the doubling
time of cytomegalovirus (CMV) in a cohort of solid organ and stem
cell recipients (Lodding et al., 2015). Why does the doubling time of
CMVmatter? This number is of great interest to the transplant special-
ist, as the preemptive treatment approach relies on the detection of
replicating CMV in blood before disease occurs. Regular determination
of quantitative CMV PCR testing allows selecting those patients with re-
activation of CMV in need of a preemptive treatment. Often, a quantita-
tive CMV copy threshold in blood is used to start antiviral treatment.
Neither the optimal frequency of CMV testing nor the ideal source
of CMV PCR (whole blood, or plasma), nor the optimal threshold has
been established. Thus, protocols between transplant centers vary. The
recently published updated international consensus guidelines on the
management of cytomegalovirus in solid-organ transplantation recom-
mended weekly testing for 3–4 months, with moderate evidence
(Kotton et al., 2013). For most centers, however, it would be very difﬁ-
cult to adhere to such a tight schedule, in particular later after transplan-
tation. Therefore, a precise knowledge of the doubling timewould allow
to safely widen the interval between CMV PCR testing, without an
increase in CMV disease episodes. The main ﬁnding of the study by
Lodding and colleagues is a CMV doubling time of 4.3 days (median,
IQR 2.5–7.8), which in contrast to earlier studies is considerably longer.
Neither the donor–recipient CMV sero-constellation nor the type of
transplant did inﬂuence these results. Earlier studies by V. Emery and
P. Grifﬁths in bonemarrow transplant patients estimated a shorter dou-
bling time of CMV of 1.5 days (median, range 0.38–4.7) (Emery et al.,
1999). Similar doubling times were calculated in a cohort of liver trans-
plant recipients (2 days (median, 0.1–69)) (Nebbia et al., 2007). Many
factors may have inﬂuenced these different estimates, including the
intensity of immunosuppression, the type of sample used for CMV PCR
detection, frequency of measurement, type of transplantation, or per-
centage of patients at high risk for CMV reactivation. While some are
less likely than other to play a role, data on the inﬂuence of these factors
on the doubling time are conﬂicting.
Interestingly, in their simulation model, Lodding and colleagues
were able to predict their real rate of recipients with a high CMV viral
load (1.4%, arbitrarily set at N18,200 IU/mL) with the assumption of
their lower doubling time of 4.3 days. Using a shorter doubling time ofDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.05.003.
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bling times, the screening interval can be safely extended. While this
may decrease the cost burden due to less visits and screening costs, it
should be emphasized that the most important goal is to reduce symp-
tomatic CMV episodes in these vulnerable patients.We and others have
shown that many factors including as strict adherence to a guideline
with timely start of antiviral therapy in case of reactivation contribute
to the success of the preemptive approach (Greiner et al., 2012). Of
note, the number of patients with CMV disease was rather high and
reached 31% during the observation time in the study by Lodding and
colleagues.
The basis of any informed decision on how to adapt the screening
schedule is a precise knowledge of the rate of CMV disease episodes in
its own institution. Such information is crucial to recognize a relevant
increase in the rate of CMV disease once changes of the preemptive pro-
tocol have been implemented. Any change in clinical routine should
be accompanied by a careful evaluation of its effect on the pertinent
endpoints. The importance of the role of carefully maintained cohorts
such as the one built and used to by Lodding and colleagues to answer
such questions in a real-life environment cannot be overstated.
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